Hemolysis from platelet transfusion: Call to action for an underreported reaction

Transfusion

Volumn 52, Issue 10, 2012, Pages 2072-2074

  Quillen, Karen ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HEMOGLOBIN;

APHERESIS; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; COOMBS TEST; EDITORIAL; HEALTH CARE POLICY; HEMATOPOIETIC STEM CELL; HEMOLYSIS; HUMAN; IMMUNIZATION; KIDNEY FUNCTION; PATIENT MONITORING; PATIENT SAFETY; RISK FACTOR; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY; UNITED KINGDOM; WORKLOAD;

ABO BLOOD-GROUP SYSTEM; ANEMIA, HEMOLYTIC; BLOOD GROUP INCOMPATIBILITY; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; PLASMA; PLATELET TRANSFUSION;

EID: 84868270184     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03839.x     Document Type: Editorial

References (15)

1. Murphy S,. ABO blood groups and platelet transfusion. Transfusion 1988; 28: 401-2.
2. Cooling L,. ABO and platelet transfusion therapy. Immunohematology 2007; 23: 20-33.
3. US Department of Health and Human Services. he 2009 national blood collection and utilization survey report. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011. [cited 2012 Jul 17]. Available from: URL: http://www.aabb.org
4. Pietersz R, Engelfriet C, Reesink H,. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005; 88: 207-21.
5. Lozano M, Heddle N, Williamson L, Wang G, AuBuchon JP, Dumont LJ,; Biomedical Excellence for Safer Transfusion Collaborative. Practices associated with ABO-incompatible platelet transfusions: a BEST collaborative international survey. Transfusion 2010; 50: 1743-8.
6. Fung MK, Downes KA, Shulman I,. Transfusion of platelets containing ABO-incompatible plasma. Arch Pathol Lab Med 2007; 131: 909-16.
7. Daniel-Johnson J, Leitman S, Klein H, Alter H, Lee-Stroka A, Scheinberg P, Pantin J, Quillen K,. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009; 49: 1845-9.
8. Quillen K, Sheldon SL, Daniel-Johnson JA, Lee-Stroka AH, Flegel WA,. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011; 51: 92-6.
9. Keller-Stanislawski B, Lohmann A, Gunay S, Heiden M, Funk MB,. The German Haemovigilance System-reports of serious adverse transfusion reactions between 1997-2007. Transfus Med 2009; 19: 340-9.
10. US Food and Drug Administration, Center for Biologics Evaluation and Research. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2011. [cited 2012 Jul 17]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/ TransfusionDonationFatalities/ucm302847.htm
11. Fauzie D, Shirey RS, Thoman S, Bensen-Kennedy D, King KE,. The risk of hemolytic transfusion reactions due to passively-acquired ABO antibodies [abstract]. Transfusion 2004; 44: 36A.
12. Karafin MS, Blagg L, Tobian AA, King KE, Ness PM, Savage WJ,. ABO antibody titers are not predictive of hemolytic reactions due to plasma incompatible platelet transfusions. Transfusion 2012; 52: 2084-90.
13. Fontaine MJ, Mills AM, Weiss S, Hong WJ, Viele M, Goodnough LT,. How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products. Transfusion 2012; 52: 2078-82.
14. Karafin MS, Fuller AK, Savage WJ, King KE, Ness PM, Tobian AA,. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012; 52: 1221-7.
15. Finlay HE, Cassorla L, Feiner J, Toy P,. Designing and testing a computer-based screening system for transfusion-related acute lung injury. Am J Clin Pathol 2005; 124: 601-9.